KIT and neoplasm: In addition, the KIT mutation co-occurred with CCND1 amplification in 0.33% (1/302), 0.82% (3/367), and 0.57% (2/350) of tumor samples in the Geneplus, TCGA, and MSKCC cohorts, respectively (Figures 1B–D).